Yvette Klein
Pembroke Pines, FLNPI 1285716258
Payments from drug & device makers
Across 94 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$522
- Hologic Sales And Service, LLC$252
- Evofem Biosciences, Inc.$139
- Therapeuticsmd, Inc.$92
- Mayne Pharma Commercial LLC$91
- Bayer$91
- plus $622 from 16 others
What the payments were for
- Food & beverage$1,79699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $522 |
| Hologic Sales And Service, LLC | 12 | $252 |
| Evofem Biosciences, Inc. | 7 | $139 |
| Therapeuticsmd, Inc. | 5 | $92 |
| Mayne Pharma Commercial LLC | 5 | $91 |
| Bayer | 4 | $91 |
| Agile Therapeutics, Inc. | 5 | $90 |
| Pfizer | 4 | $79 |
| Exact Sciences | 3 | $66 |
| Exeltis, USA Inc. | 3 | $62 |
| Avion Pharmaceuticals | 4 | $52 |
| Viiv Healthcare Company | 2 | $51 |
| Optumhealth Care Solutions, LLC | 2 | $39 |
| Millicent US Inc | 2 | $36 |
| Astellas Pharma US Inc | 1 | $33 |
| Mylan Pharmaceuticals Inc. | 1 | $25 |
| Innovation Technologies Inc | 1 | $18 |
| Lupin Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Coopersurgical, Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 27 | $11,695 |
| Estradiol | 34 | $1,016 |
| ValacyclovirValacyclovir Hcl | 21 | $433 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 15 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $79 | $11,69527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.